Global Rx-360 Consortium Aims To Curb Supply Chain Threats
This article was originally published in The Tan Sheet
Drug manufacturers formed the Rx-360 consortium as a vanguard in protecting the global supply chain of ingredients for Rx and nonprescription drug products from threats like the heparin adulteration potentially linked to 146 U.S. deaths in 2008
You may also be interested in...
FDA plans to hold a public workshop this spring to begin the task of combating profit-motivated adulteration of regulated products
BEIJING - As FDA leaders select inspectors to deploy across three offices being set up in China, the agency is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drug manufacturers that export to the U.S
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.